akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Monday, November 24, 2014

Company News: Curetis Closes EUR 14.5 Million Extension of Series B Financing

-      Curetis wins new investors QIAGEN and LSP-HEF, committing EUR 7 million

-      Curetis well financed into 2017

Curetis AG, a developer of next-level molecular diagnostic solutions, today announced it has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013. All existing investors – aeris Capital, BioMed Invest, CD Venture, Forbion Capital, HBM Partners, LSP – Life Sciences Partners, Roche Venture Fund, management, a trustee-pool of Curetis employees and private angel investors – participated in the extension financing, investing EUR 7.5 million on a pro rata basis. QIAGEN and LSP Health Economics Fund (LSP-HEF) are joining as new investors, committing a total of EUR 7 million. The financing brings the total amount of equity raised by Curetis AG to over EUR 63.5 million.

Thursday, October 9, 2014

Company News: Curetis Joins European Prosthetic Joint Infection Cohort Study (EPJIC)

-      Unyvero i60 ITI cartridges to be run on 500 prospectively collected patient samples from multi-center study across Europe

-      All Unyvero testing to be conducted in central reference lab under the auspices of the PRO-IMPLANT Foundation and Prof. Andrej Trampuz

Curetis AG, a developer of next-level molecular diagnostic solutions, today announced it has joined the European Prosthetic Joint Infection Cohort Study (EPJIC). EPJIC is an initiative of the PRO-IMPLANT Foundation to improve the management of Prosthetic Joint Infection (PJI) and to develop consensus guidelines across Europe. PJI is one of the leading causes of joint implant failure. Treatment often requires multiple surgical interventions and prolonged antibiotic therapy and is associated with a failure rate of 10 to 20 percent.